SCHEMBL375375

SCHEMBL375375

CCc1ccc(Nc2ccc(Nc3ccc(CC)cc3)c3c2C(=O)c2ccc(C)cc2C3=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY4 P51582 4/20 0.50
▸ MAPT P10636 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ TDP1 Q9NUW8 3/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ APAF1 O14727 1/20 0.44
▸ MITF O75030 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ P2RY2 P41231 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13893952 0.87 P2RY4 (0.57) P2RY4MAPTLMNATDP1NPC1
SCHEMBL6067543 0.85 MAPT (0.64) P2RY4MAPTLMNATDP1NPC1
SCHEMBL3975751 0.84 P2RY4 (0.62) P2RY4MAPTLMNATDP1NPC1
SCHEMBL13962358 0.82 P2RY4 (0.48) P2RY4MAPTLMNATDP1NPC1
SCHEMBL4660659 0.79 LCK (0.40) P2RY4MAPTLMNATDP1NPC1
SCHEMBL13346025 0.78 P2RY4 (0.54) P2RY4MAPTLMNATDP1MAPK1
SCHEMBL11540883 0.77 P2RY4 (0.61) P2RY4MAPTLMNATDP1NPC1
SCHEMBL13893905 0.77 MEN1 (0.74) P2RY4MAPTLMNATDP1NPC1
SCHEMBL13346031 0.76 P2RY4 (0.54) P2RY4MAPTLMNATDP1RAB9A
SCHEMBL35556 0.76 P2RY2 (0.60) P2RY4MAPTLMNATDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1538154-B1 Quencher composition comprising anthraquinone moieties EXIQON AS (DK) 2008-12-31 — — EP claimed
EP-1831394-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME Exiqon A/S (DK) 2007-09-12 — — EP claimed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 — — US claimed
WO-2006066592-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME EXIQON A/S (DK) 2006-06-29 — — WO claimed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 — — US claimed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 — — EP claimed
US-20140227689-A1 NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON A/S (DK) 2014-08-14 — — US disclosed
US-8383344-B2 Methods for quantification of microRNAs and small interfering RNAs EXIQON A/S (DK) 2013-02-26 — — US disclosed
US-8192937-B2 Methods for quantification of microRNAs and small interfering RNAs EXIQON A/S (DK) 2012-06-05 — — US disclosed
EP-1735459-B1 METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON AS (DK) 2012-01-25 — — EP disclosed
US-20110076675-A1 NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS EXIQON A/S (DK) 2011-03-31 — — US disclosed
US-7504495-B2 Quencher compositions comprising anthraquinone moieties EXIQON A/S (DK) 2009-03-17 — — US disclosed
EP-1538154-B1 Quencher composition comprising anthraquinone moieties EXIQON AS (DK) 2008-12-31 — — EP disclosed
US-20080076674-A1 Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer EXIQON A/S (DK) 2008-03-27 — — US disclosed
EP-1831394-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME Exiqon A/S (DK) 2007-09-12 — — EP disclosed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 — — US disclosed
WO-2006066592-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME EXIQON A/S (DK) 2006-06-29 — — WO disclosed
US-20050272075-A1 Novel methods for quantification of microRNAs and small interfering RNAs QIAGEN GMBH (DE) 2005-12-08 — — US disclosed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 — — US disclosed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties ANXA5, SUN2, ANXA3 P2RY4 358/4885MAPT 4696/4885LMNA 522/4885
US-20080076674-A1 Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer SNRPE, SNRPA, NOP56 P2RY4 4594/4885MAPT 3561/4885LMNA 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback